Figure 1.

Percentage of circulating monocytes in patients with RA at baseline and over anti-TNFα treatment. The absolute number (cells/μl) of circulating monocytes (panel A), CD14^+highCD16^- (panel B), CD14^+highCD16⁺ (panel C) and CD14^+lowCD16⁺ monocytes (panel D) of non-responders (□) and responders (○) at baseline and after three and six months of MTX treatment, and of healthy controls (▼), are shown as the mean ± SEM. * significant difference between patients with RA and healthy controls. † significant difference between non-responders and responders. ‡ significant difference between baseline and six-month values.